Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 12/20 | 1.00 |
| ▸ | JAK1 | P23458 | 18/20 | 0.87 |
| ▸ | TYK2 | P29597 | 8/20 | 0.80 |
| ▸ | JAK3 | P52333 | 5/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22648730 | 0.93 | JAK1 (1.00) | JAK2JAK1TYK2JAK3HDAC6 | |
| SCHEMBL22648790 | 0.93 | JAK1 (1.00) | JAK2JAK1TYK2JAK3HDAC6 | |
| SCHEMBL22648744 | 0.92 | JAK1 (0.98) | JAK2JAK1TYK2JAK3HDAC6 | |
| SCHEMBL22648713 | 0.91 | JAK1 (0.95) | JAK2JAK1TYK2JAK3HDAC6 | |
| SCHEMBL22648892 | 0.89 | JAK1 (1.00) | JAK2JAK1TYK2JAK3HDAC6 | |
| SCHEMBL22696571 | 0.86 | JAK1 (0.82) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL22648782 | 0.86 | JAK1 (0.81) | JAK2JAK1TYK2JAK3HDAC6 | |
| SCHEMBL22648758 | 0.86 | JAK1 (1.00) | JAK2JAK1TYK2JAK3HDAC6 | |
| SCHEMBL22648774 | 0.86 | JAK1 (1.00) | JAK2JAK1TYK2JAK3HDAC6 | |
| SCHEMBL22648787 | 0.86 | JAK1 (0.93) | JAK2JAK1TYK2JAK3HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136329-B2 | JAK inhibitors | VIMALAN BIOSCIENCES, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-11136329-B2 | JAK inhibitors | VIMALAN BIOSCIENCES, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200369669-A1 | JAK INHIBITORS | VIMALAN BIOSCIENCES, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20200369669-A1 | JAK INHIBITORS | VIMALAN BIOSCIENCES, INC. | 2020-11-26 | — | — | US | disclosed |
| WO-2020227563-A1 | JAK INHIBITORS | VIMALAN BIOSCIENCES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369669-A1 | JAK INHIBITORS | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885TYK2 8/4885 |
| US-11136329-B2 | JAK inhibitors | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885TYK2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.